IMR Press / EJGO / Volume 22 / Issue 6 / pii/2001211

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan

Show Less
1 Uludag University Medical Faculty, Department of Obstetrics and Gynaecology, Turkey
2 Uludag University Medical Faculty, Department of Haematology, Turkey
3 Uludag University, Experimental Animals Research Laboratory, Bursa, Turkey
Eur. J. Gynaecol. Oncol. 2001, 22(6), 463–465;
Published: 10 December 2001
Abstract

Purpose: To investigate the efficacy and safety of single-dose filgrastim administered 24 hours prior to chemotherapy in the prevention of topotecan-related myeloid suppression. Methods: No medication was given to 21 rats in group I; 1.5 mg/m2/day topotecan was administered intraperitoneally for five days every three weeks to 21 rats in group II; a single dose of 5 µg/kg filgrastim was injected intraperitoneally 24 hours before the intraperitoneal administration of the same dose of topotecan to 21 rats in group III. After completion of six cycles of chemotherapy, the rats were decapitated and blood samples were immediately collected into citrated tubes for complete blood counts. Results: White blood cell and lymphocyte counts in the control and the filgrastim + topotecan groups were similar (p > 0.05) and significantly higher than tlie counts in the topotecan group (p < 0.05). There was no difference in means of neutrophil, monocyte, eosinophil, basophil and erythrocyte counts among the groups (p > 0.05). Conclusion: Filgrastim administration prior to chemotherapy seems to be beneficial and further investigations are needed.

Keywords
Filgrastim
Topotecan
Prechemotherapy
Myelosuppression
Share
Back to top